Evotec ESG Presentation Deck
evotec
Key challenges
R&D model is inefficient
"One drug fits all"
Biologics are complex
Emerging technologies
PAGE 3
Dynamics in industry suggest need for disruptive approach
Current challenges in R&D
Increasing costs and
decreasing returns
90% of drugs efficacious only in
50% of patients
9% of Phase I biologics receive
approval¹)
Precision medicine toolkit,
OMICS platforms, and AI/ML
Development costs per asset increase
Cost per asset increased ~2/3rd since 2010, in US$ m
~1,981
1,188
2010
2019
Commercial returns decrease
IRR since 2010
~10
2010
~2
2019
¹) https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2021/files/reports/2021-clinical-development-success-rates-2011-2020-v17.pdf
Sources: Deloitte - Centre for Health Solutions: Ten years on measuring the return of pharmaceutical innovation 2019; Evaluate Pharma - World Preview 2018 / World Preview 2020
-80%
+67%View entire presentation